With a market cap of $12.8 billion, The Clorox Company (CLX) is a leading consumer products company dedicated to helping people be well and thrive every day. Through consumer-centric innovation and a strong commitment to sustainability, Clorox delivers trusted brands such as Brita®, Burt’s Bees®, Clorox®, Glad®, Hidden Valley®, Kingsford®, Pine-Sol® and Purell®, along with a portfolio of international brands.
Shares of the Oakland, California-based company have underperformed the broader market over the past 52 weeks. CLX stock has fallen 13.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.6%. Moreover, shares of the company are up 5.3% on a YTD basis, compared to SPX’s 13.9% rise.
Looking closer, the consumer products maker stock has lagged behind the State Street Consumer Staples Select Sector SPDR ETF’s (XLP) 4.1% return over the past 52 weeks.
Shares of Clorox soared 6.5% following its Q4 2026 results on Aug. 3, as the company forecast fiscal 2027 net sales growth of 13% - 14%, above analysts’ estimates, signaling improving demand in its health and wellness segments and internationally. The company also reported better-than-expected Q4 sales of $1.95 billion and adjusted EPS of $1.66. Investor sentiment was further supported by Clorox’s $2.25 billion acquisition of GOJO Industries, although its outlook for adjusted fiscal 2027 EPS of $5.70 - $6.00 remained below analysts’ and gross margin fell 520 basis points to 41.3%.
For the fiscal year ending in June 2027, analysts expect Clorox’s adjusted EPS to grow 5.2% year-over-year to $5.82. The company’s earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing on another occasion.
Among the 18 analysts covering the stock, the consensus rating is a “Hold.” That’s based on 13 “Hold” ratings and five “Strong Sells.”
This configuration is less bullish than three months ago, with one “Strong Buy” rating on the stock.
On Aug. 4, JPMorgan analyst Andrea Teixeira raised its price target for Clorox to $95 while maintaining an “Underweight” rating.
As of writing, the stock is trading above the mean price target of $96.94. The Street-high price target of $117 suggests a 10.9% potential upside.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/The%20sign%20for%20Marvell%20Technology%20out%20front%20of%20a%20corporate%20office%20by%20Valeriya%20Zankovych%20via%20Shutterstock.jpg)
/The%20front%20of%20a%20Rocket%20Lab%20corporate%20office%20by%20Emagnetic%20via%20Shutterstock.jpg)
